You are here

gefapixant

Merck’s Chronic Cough Drug Fails to Secure FDA Approval for Second Time

BioSpace

Thu, 12/21/23 - 11:36 am

After watching Merck's chronic cough drama, GSK knew exactly what not to do with Bellus asset

Fierce Biotech

Thu, 11/30/23 - 10:07 am

FDA panel flags insufficient data for Merck's chronic cough drug

Reuters

Sun, 11/19/23 - 09:32 pm

FDA skeptical of Merck’s gefapixant, even after cough recount

Fierce Biotech

Thu, 11/16/23 - 11:34 am

Merck plans to count coughs and months until gefapixant is back in FDA hands

Fierce Biotech

Fri, 08/5/22 - 10:54 am

Merck: FDA Rejects Gefapixant Application, Requests More Data

Marketwatch

Mon, 01/24/22 - 10:22 am

Bellus soars on positive mid-stage readout for its Merck cough rival, despite a failure in atopic dermatitis

Endpoints

Mon, 12/13/21 - 11:06 am

FDA says it needs a little more time to decide on Merck's P2X3 for chronic cough

Endpoints

Thu, 08/12/21 - 11:12 am

Chasing Merck & Co, Bayer builds case for cough drug eliapixant

Pharmaforum

Wed, 08/4/21 - 10:49 am

clinical trials

FDA accepts gefapixant for review in cough, positioning Merck to get head start on Bayer and Bellus

Fierce Biotech

Mon, 03/1/21 - 10:38 am

Merck's gefapixant successful in late-stage chronic cough studies

Seeking Alpha

Tue, 09/8/20 - 11:00 am

clinical trials

Merck hits goal in cough phase 3 but yet to quash tolerability concern

Fierce Biotech

Tue, 03/17/20 - 12:14 pm

clinical trials